^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | nazartinib (EGF816) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Excerpt:
...- Patients must have histologically or cytologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC....
Source:
Title:
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Excerpt:
...- An EGFR sensitizing mutation must be detected in tumor tissue....
More C2 evidence
Source:
Title:
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Excerpt:
...- Histologically documented locally advanced or metastatic, stage IIIB/ IIIC or stage IV NSCLC with documented EGFR activating mutation (L858R or ex19del)...
Trial ID:
Less C2 evidence
Source:
Title:
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study
Published date:
07/07/2022
Excerpt:
First-line nazartinib demonstrated promising efficacy, including clinically meaningful antitumor activity in the brain, and manageable safety in patients with EGFR-mutant NSCLC.
DOI:
10.1016/j.ejca.2022.05.023
Source:
Title:
Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).
Published date:
05/16/2018
Excerpt:
Oral nazartinib demonstrated a tolerable safety profile...Promising efficacy in treatment-naïve pts with EGFR-mutant NSCLC was seen despite a high number of pts with brain metastases.
DOI:
10.1200/JCO.2018.36.15_suppl.9094
Trial ID:
